80% of Rectal Cancer Patients Keep Their Rectum in New Trial

Thousands of rectal cancer patients may soon avoid the devastating side effects of major surgery, thanks to a breakthrough trial that's rewriting treatment guidelines.

The STAR-TREC trial, funded by Cancer Research UK and Stand Up To Cancer, studied over 500 early-stage rectal cancer patients across five countries. Researchers discovered that five weeks of chemoradiotherapy allowed 80% of patients to keep their rectum and skip the radical surgery that often results in permanent colostomy bags, sexual dysfunction, and urinary problems.

Brian, a 69-year-old from Birmingham, was one of those patients. After noticing bleeding and changes in his bowel habits, he expected a hemorrhoid diagnosis but learned he had rectal cancer instead.

"My consultant explained that the usual treatment would be surgery and it was highly likely I'd be left with a permanent colostomy bag," Brian recalls. "The decision wasn't difficult, so I said, 'sign me up.'"

He underwent five days of intensive radiotherapy with minimal side effects beyond slight nausea and back pain. Today, all his scans show no trace of cancer.

The trial compared three approaches: standard surgical removal of the entire rectum, five weeks of chemoradiotherapy, or five days of radiotherapy. After 12 months, the five-week chemoradiotherapy group needed radical surgery far less often than the other groups.

Around 4,100 people in England receive early-stage rectal cancer diagnoses each year. For them, this could mean the difference between invasive surgery with permanent lifestyle changes and a treatment that preserves both their organ and quality of life.

The Ripple Effect

This isn't just about one type of cancer or one country. The success of STAR-TREC demonstrates how smarter, kinder treatments can replace aggressive approaches that worked but came at tremendous personal cost.

Professor David Sebag-Montefiore from the University of Leeds calls it "an example of how a smarter, kinder radiotherapy treatment may allow patients to avoid the need for major surgery." Michelle Mitchell, Cancer Research UK's chief executive, agrees: "This breakthrough could be life-changing for thousands of people."

The research team will monitor patients for three more years to ensure the cancer stays away and survival rates remain strong. If the results hold, the next challenge is making this treatment available to every eligible patient.

Brian is back to supporting Millwall Football Club and traveling. "Success stories like mine wouldn't be possible without research into better and kinder treatments," he says.

Clinical trials like STAR-TREC prove that sometimes the best path forward isn't doing more, it's doing smarter.